A2W-PHARMA-LTD
6.4.2022 18:02:11 CEST | Business Wire | Press release
A2W Pharma Ltd, a pharmaceutical company based in Malta, celebrates the opening of its new facility during a launch event on its premises today. The event is addressed by Hon. Miriam Dalli – Minister for Environment, Energy and Enterprise, H.E. Yu Dunhai – Ambassador of China to Malta, Peter Paul Farrugia - A2W Pharma Director, Antonio Sommei - Amino Chemicals CEO, and Kurt Farrugia - Malta Enterprise CEO, along with representatives from Malta Medicines Authority.
A2W provides full end to end processing from raw material to bottling with chemical and stability testing capabilities. The company has begun validating materials and methods, and is expecting to receive its EU-GMP certification this summer. Its long-term vision centres around the development of botanical active substances for pharmaceutical and nutraceutical product development.
“The opening of A2W Pharma is part of our strategic vision to extend the capabilities of our operations in Malta to support our partners in the development of pharmaceutical formulations,” says Antonio Sommei.
The mother company, ABA Chemicals Corp (Shenzen Stock Exchange 300261-CN:Shenzhen) has invested more than €6 million, through its API facility, Amino Chemicals Ltd, to address an immediate demand for EU-GMP certified extracts. Amino, also based in Malta, has 30 years of experience developing pharmaceutical APIs and lends its commercial and regulatory expertise.
“The discoveries related to the active substances found in the cannabis plant, and their therapeutic effects, represent a shift in the way patients suffering from various ailments can be treated. A2W’s vision is to increase access to these substances, whilst utilising 30 years of experience in pharmaceutical development to ensure adherence to the strictest of regulatory requirements,” says Tony Cai, ABA Chemicals Chairperson.
A2W’s long-term strategy centers around developing pharmaceutical products for therapeutic areas where there is a critical need to advance patient care. The medical cannabis industry, globally valued at USD 22 billion, is expected to continue its tremendous growth as more countries legalize prescription use to treat neurological and immunological conditions. Industry growth can be attributed to physician education and patient awareness regarding the benefits of medical cannabis.
“We are fortunate to have the support and expertise of ABA and Amino to help us achieve our goal of entering this new sector of pharmaceutical development, which we aim to enhance with our experience and capabilities,” says Peter Paul Farrugia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005057/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Appoints Iwan Röpcke as Chief Executive Officer, Belgium8.5.2026 09:30:00 CEST | Press release
The Fortegra Group, Inc., a global specialty insurer, today announced the appointment of Iwan Röpcke as Chief Executive Officer, Belgium. Mr. Röpcke brings more than 25 years of insurance industry experience to the role, spanning broking, commercial leadership, and executive management across the Benelux and broader European markets. He joins Fortegra from Lloyd’s Insurance Company S.A., where he served as Country Manager for Belgium and the Netherlands, building out the operation from its early stages and overseeing both business strategy and development. Prior to Lloyd's, Mr. Röpcke held senior leadership positions at Willis Towers Watson (via Gras Savoye), where he served as Head of Sales and Head of the Competence Center. His career also includes roles at Inter Partner Assistance (AXA Assistance) as Commercial Director Benelux, Winterthur Europe Assurances, AIG Europe, Aon Belgium, and Marsh. Mr. Röpcke’s industry expertise spans a range of specialty risk areas, with deep relations
KAYTUS Launches All-QLC Flash Storage at AI EXPO 2026 for 10,000-GPU Clusters8.5.2026 09:02:00 CEST | Press release
KAYTUS’s next-generation all-QLC flash solution delivers fully linear performance scaling for massive GPU clusters, while reducing TCO by 70%, enabling ultra-large-scale computing for the era of agentic AI. At AI EXPO KOREA 2026, KAYTUS officially launched its All-QLC Flash Storage Solution, engineered to deliver high performance, massive scalability, and cost efficiency for 10,000-GPU clusters. The solution addresses data-delivery bottlenecks in ultra-large-scale AI training, helping maximize GPU resource utilization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260508313130/en/ Based on the KR2280 and KR1180 server platforms, the solution is deeply integrated with industry-leading AI-native parallel file systems to eliminate data silos inherent in traditional tiered storage. Purpose-built for read-intensive AI workloads, it overcomes the horizontal scaling limitations of massive clusters. Verified test-data shows that, a
Beneq Appoints Dr. Jason Harrison as Chief Executive Officer8.5.2026 09:00:00 CEST | Press release
Semiconductor industry leader takes the helm to accelerate Beneq’s next phase of growth in atomic layer deposition Beneq Oy, the home of atomic layer deposition (ALD), today announced the appointment of Dr. Jason Harrison as Chief Executive Officer. Dr. Harrison succeeds Dr. Tommi Vainio and will lead Beneq into its next phase of growth across semiconductor, optical, and emerging technology markets. A Strategic Leadership Transition Beneq enters its next phase of growth from a position of strong commercial momentum. Recent milestones include the qualification of the Beneq Transform® cluster tool for volume production of GaN power and RF filter devices; the introduction of Beneq Transmute™ and Beneq Transform® XP, both engineered for high-volume manufacturing (HVM) of specialty semiconductors; growing adoption of the P-Series for coating critical chamber parts in advanced node devices; and selection of the C2R™ for AR waveguide production in next-generation XR optics. Against this backd
World Employment Confederation’s 59th Annual Conference to Address Critical Global Labour Market Concerns8.5.2026 07:12:00 CEST | Press release
Senior leaders from policy, business and international institutions are set to discuss critical labour market concerns at the World Employment Confederation’s Annual Conference, during an era of global transformation and disruption never-before-seen. Taking place on 12-13 May in Toronto and entitled ‘Grow With Talent’, this year’s World Employment Conference – co-organised with ACSESS – arrives at a time of profound economic uncertainty. This gathering of leaders and experts will help define the path forward for the global labour market and set the stage for discussions at the 114th Session of the International Labour Conference (ILC) in June. Bettina Schaller, President of World Employment Confederation (WEC) says: “The question at the heart of this year’s World Employment Conference is: how will we mobilise the world’s talent to drive growth in an era of disruption?At a time of accelerating AI adoption, rapid demographic change and an uncertain global economic outlook, pressure on la
Esentia Announces Successful Pricing of 6.125% Senior Notes Due 2033 and 6.500% Senior Notes Due 20388.5.2026 03:24:00 CEST | Press release
Esentia Energy Development, S.A.B. de C.V. (“ESENTIA” or the “Company”), today announced the pricing of U.S.$1,000,000,000.00 aggregate principal amount of its 6.125% Senior Notes due 2033 (the “2033 Notes”) and U.S$1,000,000,000.00 aggregate principal amount of its 6.500% Senior Notes due 2038 (the “2038 Notes” and, together with the 2033 Notes, the “Notes”) to be issued by the Company in a private offering to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons in accordance with Regulation S under the Securities Act. The 2033 Notes will be issued at a price of 99.517%, and the 2038 Notes will be issued at a price of 98.444%. The 2033 Notes mature on July 30, 2033, and the 2038 Notes mature on July 30, 2038, and will be fully and unconditionally guaranteed by certain of the Company's subsidiaries. The settlement of the Notes is expected to take place on May 14
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom